Innovent Biologics, Inc. (HKG:1801)
50.30
+0.45 (0.90%)
Apr 3, 2025, 3:59 PM HKT
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
1.77M HKD
Profits / Employee
-17.80K HKD
Market Cap
81.66B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
BeiGene | 11,000 |
Hansoh Pharmaceutical Group Company | 8,989 |
WuXi Biologics | 12,575 |
JD Health International | 3,564 |
Alibaba Health Information Technology | 1,435 |
Akeso | 2,778 |
Sino Biopharmaceutical | 24,379 |
Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
Innovent Biologics News
- 3 days ago - Innovent Biologics Inc (IVBIY) Secures Breakthrough Therapy Designation for IBI363 in Melanoma ... - GuruFocus
- 3 days ago - Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma - PRNewsWire
- 6 days ago - Innovent Biologics reports FY results - Seeking Alpha
- 7 days ago - Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting - PRNewsWire
- 7 days ago - Innovent Announces 2024 Annual Results and Business Updates - PRNewsWire
- 10 days ago - Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer - PRNewsWire
- 15 days ago - Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - PRNewsWire
- 20 days ago - China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease - PRNewsWire